RLAY: Bull Flag detected on 21 Aug 2026

RLAY is forming a bull flag pattern as a clinical-stage, small molecule precision medicine company. The stock sits at $19.70 between support at $17.71 and resistance at $20.79, with a conservative target of $20.35. Structure score of 14.7/15 and breakout score of 11.2/13 indicate solid pattern geometry and emerging upside momentum. Volume ratio of 1.27x average shows adequate participation. Overall score of 76.1/98 and win probability of 74.17% suggest this is a credible setup, though not elite-tier. The stock has gained 51.31% over three months and sits 551% above its 52-week low, reflecting pronounced uptrend context.

RLAY reported Q1 2026 results on May 5, 2026, securing FDA Breakthrough Therapy designation for zovegalisib in PIK3CA-mutant HR+/HER2- advanced breast cancer with an 11.1-month median PFS. A fresh $175 million equity raise in May expanded share authorization and funds an unprofitable model. The Q2 2026 update due August 6, 2026 represents a near-term sentiment check focused on zovegalisib's Phase 3 trajectory as the main catalyst. Recent earnings-beat optimism and strong share price run suggest expectations are already elevated, which can amplify the impact of even modest data or guidance surprises. This pattern is forming just before an earnings event that investors view as pivotal for trial execution credibility.

A successful bull flag breakout would clear the $20.79 resistance level, targeting the conservative upside objective of $20.35 (representing a modest 3.3% move from current price). Volume confirmation should remain above 1.20x average as the breakout confirms. The setup fails if price closes below key support at $17.71, invalidating the flag structure—approximately 10% downside risk. With a 74.17% historical win probability for this pattern type, the odds favor directional resolution upward, though the tight target range and neutral market regime limit the upside potential relative to risk.

Recent earnings-beat optimism and elevated share price expectations can amplify the impact of even modest data surprises in negative directions. Prior earnings-date announcements produced mixed 24-hour reactions of 3.1% and -1.81%, indicating unpredictable event risk around Q2 results dated August 6. The August 6 earnings release is just 16 days away—a critical near-term event that could break this flag pattern prematurely. RSI at 52.47 is neutral (not overbought), but the stock's 551% run above 52-week lows and 51% three-month gain create elevated downside vulnerability if trial or guidance disappointments emerge. Clinical-stage biotech inherently carries binary execution risk around zovegalisib Phase 3 trial outcomes.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.